Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CTOR
Strong SellSinkerCitius Oncology, Inc. · Healthcare · United States · $82M · Avg Vol: $98K/d
COMPANY DESCRIPTION
Citius Oncology, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel oncology therapeutics, including its lead asset LYMPHIR for cutaneous T-cell lymphoma. The company's competitive advantage lies in its targeted focus on late-stage, niche oncology indications with clear regulatory pathways and high unmet medical needs. It operates as a specialized developer in the oncology sector, leveraging strategic partnerships for commercialization.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 13.9M | 95.2M | — |
| EPS | -0.08 | -0.18 | -0.31 | -0.34 | — | -0.48 | -0.56 | 0.10 | — |
| Shares | 71.2M | 71.2M | 71.6M | 83.5M | +17.2% | 105.8M | — | — | — |
| Debt | — | — | 3.8M | 3.8M | 0.0% | 10.2M | — | — | — |
| Equity | 36.3M | 25.5M | 46.1M | 44.9M | 7.3% | — | — | — | — |
| Op CF | 0 | 0 | 0.1M | -5.5M | — | -19.4M | — | — | — |
| Inv CF | — | 0 | -5.0M | -5.8M | — | — | — | — | — |
| Fin CF | — | 0 | 4.9M | 15.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTOR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CTOR | Citius Oncology, Inc.(you) | $82M | 6 | Strong Sell |
| CWEB.TO | Charlotte's Web Holdings, Inc. | $80M | 15 | Strong Sell |
| TLPH | Talphera, Inc. | $62M | 24 | Sell |
| LFCR | Lifecore Biomedical, Inc. | $172M | 16 | Strong Sell |
| AKBA | Akebia Therapeutics, Inc. | $243M | 17 | Strong Sell |
| SCYX | SCYNEXIS, Inc. | $54M | 31 | Sell |
| DERM | Journey Medical Corporation | $211M | 24 | Sell |
| BIOA | BioAge Labs, Inc. | $443M | 9 | Strong Sell |
| CPIX | Cumberland Pharmaceuticals Inc. | $127M | 38 | Hold |
| ORGO | Organogenesis Holdings Inc. | $224M | 29 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%